Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.

Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.

Although growth hormone (GH) replacement therapy is increasingly utilized in the management of adult hypopituitary patients, optimum dosing schedules are poorly defined. The use of weight-based or surface area-based dosing may result in overtreatment, and individual variation in susceptibility on th...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Drake, WM, Coyte, D, Camacho-Hübner, C, Jivanji, N, Kaltsas, G, Wood, D, Trainer, P, Grossman, AB, Besser, G, Monson, J
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	1998

Παρόμοια τεκμήρια

Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study.
ανά: Florakis, D, κ.ά.
Έκδοση: (2000)

Comments on 'Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two-year study' by Florakis et al (2000) - Reply
ανά: Monson, J, κ.ά.
Έκδοση: (2001)

Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy.
ανά: Frajese, G, κ.ά.
Έκδοση: (2001)

Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours.
ανά: Chung, T, κ.ά.
Έκδοση: (2008)

Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients.
ανά: Agha, A, κ.ά.
Έκδοση: (2007)

Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years.
ανά: le Roux, C, κ.ά.
Έκδοση: (2002)

Role of fasting plasma glucose, glycated haemoglobin and homeostatic model assessment in the detection of glucose intolerance in adult hypopituitary patients during growth hormone replacement therapy.
ανά: Colson, A, κ.ά.
Έκδοση: (2008)

Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement.
ανά: Chung, T, κ.ά.
Έκδοση: (2005)

Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
ανά: Kaltsas, G, κ.ά.
Έκδοση: (2001)

Insulin-like growth factor-I and- II in combination inhibit the release of growth hormone-releasing hormone from the rat hypothalamus in vitro.
ανά: Korbonits, M, κ.ά.
Έκδοση: (1996)

The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults.
ανά: Sverrisdóttir, Y, κ.ά.
Έκδοση: (2003)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
ανά: Jenkins, P, κ.ά.
Έκδοση: (2000)

Growth hormone deficiency and replacement in patients with treated Cushing's Disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density.
ανά: Colson, A, κ.ά.
Έκδοση: (2006)

The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients
ανά: Irene K Oglesby, κ.ά.
Έκδοση: (2023-09-01)

The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.
ανά: Korbonits, M, κ.ά.
Έκδοση: (1999)

Hexarelin as a test of pituitary reserve in patients with pituitary disease.
ανά: Korbonits, M, κ.ά.
Έκδοση: (1999)

Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormone.
ανά: Trainer, P, κ.ά.
Έκδοση: (1992)

Authors' response: The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women
ανά: Kaltsas, G, κ.ά.
Έκδοση: (2003)

The prevalence and characteristic features of cyclicity and variability in Cushing's disease.
ανά: Alexandraki, K, κ.ά.
Έκδοση: (2009)

How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
ανά: Kaltsas, G, κ.ά.
Έκδοση: (2000)

Classic cardiovascular risk factors improve in very elderly hypopituitary patients treated on standard hormone replacement in long term follow- up
ανά: Isabella Naves Rosa, κ.ά.
Έκδοση: (2021-03-01)

CT appearance of the adrenal glands in adrenocorticotrophic hormone-dependent Cushing's syndrome.
ανά: Sohaib, SA, κ.ά.
Έκδοση: (1999)

Complications of inferior petrosel sinus sampling.
ανά: Kaltsas, G, κ.ά.
Έκδοση: (2000)

Circulating Levels of Irisin in Hypopituitary and Normal Subjects.
ανά: Lara Pena-Bello, κ.ά.
Έκδοση: (2016-01-01)

Benzodiazepines attenuate the pituitary-adrenal responses to corticotrophin-releasing hormone in healthy volunteers, but not in patients with Cushing's syndrome.
ανά: Korbonits, M, κ.ά.
Έκδοση: (1995)

Prevalence and risk factors of the metabolic syndrome in young adults with childhood-onset hypopituitary growth hormone deficiency
ανά: Han Hyuk Lim, κ.ά.
Έκδοση: (2010-10-01)

Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy.
ανά: Swords, F, κ.ά.
Έκδοση: (2009)

The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.
ανά: Kaltsas, G, κ.ά.
Έκδοση: (1998)

Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome.
ανά: Isidori, A, κ.ά.
Έκδοση: (2003)

Male-female differences in 6-sulfatoxymelatonin excretion in hypopituitary patients
ανά: Hugo L. Fideleff, κ.ά.
Έκδοση: (2016-02-01)

Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome.
ανά: Newell-Price, J, κ.ά.
Έκδοση: (2002)

NITRIC-OXIDE AS A NOVEL REGULATOR OF NEUROENDOCRINE FUNCTION - CONTROL OF CORTICOTROPIN-RELEASING HORMONE-41 RELEASE FROM THE RAT HYPOTHALAMUS INVITRO
ανά: Costa, A, κ.ά.
Έκδοση: (1992)

Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
ανά: Korbonits, M, κ.ά.
Έκδοση: (1998)

A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia.
ανά: Miraki-Moud, F, κ.ά.
Έκδοση: (2005)

A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome.
ανά: Kaltsas, G, κ.ά.
Έκδοση: (1999)

Initial response of young people with thyrotoxicosis to block and replace or dose titration thionamide
ανά: Claire L Wood, κ.ά.
Έκδοση: (2023-01-01)

Clinical, radiological and pathological features of patients with Rathke's cleft cysts: tumors that may recur.
ανά: Mukherjee, J, κ.ά.
Έκδοση: (1997)

BENZODIAZEPINES ATTENUATE THE SERUM CORTISOL RESPONSE TO CORTICOTROPIN-RELEASING HORMONE (CRH) IN HEALTHY-VOLUNTEERS
ανά: Trainer, P, κ.ά.
Έκδοση: (1992)

No clear evidence for an association between GH replacement and relapse of intracranial germ cell tumours: single centre and KIMS experience.
ανά: Chung, T, κ.ά.
Έκδοση: (2010)

Nitric oxide modulates the release of corticotropin-releasing hormone from the rat hypothalamus in vitro.
ανά: Costa, A, κ.ά.
Έκδοση: (1993)